Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 26:12:7891-7903.
doi: 10.2147/CMAR.S212526. eCollection 2020.

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

Danai Dima  1 , Joshua Dower  1 , Raymond L Comenzo  2 , Cindy Varga  2
Affiliations
Review

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

Danai Dima et al. Cancer Manag Res. .

Abstract

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains significant, highlighting the need for new effective strategies. In recent years, daratumumab, a novel human monoclonal antibody, binding CD38, has dramatically improved outcomes either as monotherapy or in combination with traditional regimens. Originally approved for relapsed/refractory multiple myeloma, this breakthrough medication is now being used as frontline therapy in patients with newly diagnosed multiple myeloma regardless of transplant eligibility, with trials showing promising results. Its tolerable side-effect profile and enhanced efficacy have led to its widespread incorporation into the management of multiple myeloma and further exploration about its use in other entities such as smoldering myeloma, MGUS, MGRS and amyloidosis. This comprehensive review will discuss daratumumab's mechanism of action and safety profile, as well as research which has defined its current approved indications, and ongoing clinical investigation that will define its future.

Keywords: daratumumab; newly diagnosed multiple myeloma; relapsed/refractory multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Dr Danai Dima and Dr Joshua Dower are co-first authors. Dr Raymond Comenzo reports a patent WO2016187546A1 issued. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Daratumumab mechanism of action.
See this image and copyright information in PMC

References

    1. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi:10.1093/annonc/mdp329 - DOI - PubMed
    1. Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–908. doi:10.1038/leu.2011.29 - DOI - PMC - PubMed
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442 - DOI - PubMed
    1. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma. - PubMed
    1. Stege CAM, Nasserinejad K, Levin M-D, et al. Efficacy and tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) patients; first interim safety analysis of the Phase II HOVON 143 Study. Blood. 2018;132(Supplement 1):596. doi:10.1182/blood-2018-99-114668 - DOI